MYALEPTA® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients

Shots:

• First and only therapy approved for LD patients with confirmed or acquired in adults and children ≥2yrs; partial or acquired LD in adults or children ≥12yrs in Europe after being approved by US FDA in 2014
• The approval will prove to be a significant advancement for patients in Europe
• Authorization was on results shown from open –label, single arm study in 48 patients

Click here to read full press release/ article | Ref:  Novelion  | Image: Business Wire